ASH 2019 | ATIR101 after haplo HSCT proves promising
Denis-Claude Roy, MD, University of Montreal, Montreal, QC, Canada, discusses the addition of ATIR101 as an adjunctive treatment given after T-cell-depleted haploidentical HSCT. Data has shown that this may decrease non-relapse mortality and improve survival in hematologic malignancies, irrespective of prognostic risk factors. A global randomized Phase 3 study is currently enrolling to further examine T-cell-depleted haplo HSCT plus ATIR101 compared with T-cell-replete haplo HSCT with post-transplant cyclophosphamide (HATCY; NCT02999854).This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up